If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
6.85    -0.25 (-3.52%)
Bid:
6.70
Ask:
7.00
Spread: 0.30 (4.478%)
Market Cap: £3.00m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Collaboration Agreement

19 Sep 2024 07:00

RNS Number : 7696E
Feedback PLC
19 September 2024
 

Feedback plc

 

Feedback signs collaboration agreement with a provider of primary care solutions

 

Feedback plc ("Feedback" or the "Company"), has signed a collaboration agreement with a provider of primary care solutions to explore the opportunities for a novel Neighborhood Diagnostics Solution.

 

The intention is to explore creating a solution that combines the partners' technology and Bleepa to streamline NHS diagnostic and pathway referrals between primary care, Community Diagnostic Centres (CDCs) and secondary care. It is envisaged the solution will also enable some diagnostic procedures to be referred into community settings such as pharmacy or other diagnostic facilities, creating additional diagnostic capacity to support NHS waitlist recovery.

 

The parties intend to pilot the solution before pursuing broader national opportunities for contracts. Pilot conversations with customer sites are already underway. A pilot will seek to demonstrate both the continued reduction in outpatient appointment requirement through the combined platform, further reduction in patient wait times through an optimised GP referral process and also the ability to scale the solution at pace to multiple GP practices simultaneously.

 

The collaboration provides a route to rapidly scale the Bleepa solution and pathway approach, leveraging the existing footprint of the party.

 

The Company estimates that over 190m diagnostic tests per year could be redirected to a pharmacy setting. If taken to a national scale this opportunity could represent an estimated total addressable market of £382m annually with further opportunities for potential international expansion. Commercial revenue from this potential opportunity remains subject to, inter alia, successful pilots and commercial agreement between the parties.

 

 

Dr Tom Oakley, CEO, Feedback plc said: "This collaboration aligns to the Secretary of State's vision to move care out of traditional acute provider settings and into the community, closer to patients. If successful it will provide additional capacity to the NHS and help to overcome some of the difficulties being faced by CDCs, such as recruitment challenges, by enabling redirection to fully staffed facilities. It will also offer patients' choice and the convenience of attending their local high street for routine NHS investigations with, we believe, shorter wait times.

 

"Lord Darzi's paper, released on Thursday 12th September, calls directly for this solution. Given the impact that the combined product can deliver and the ability to leverage our partners existing footprint to scale the solution the Company believes that we have a huge opportunity to support the new model of the NHS under the new Labour Administration."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018.

 

--Ends--

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Anesh Patel, CFO

+44 (0) 20 3997 7634

IR@fbk.com

 

Panmure Liberum Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley/Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

 

Walbrook PR Ltd;

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Nick Rome/Joe Walker

07748 325 236 or 07407 020 470

 

 

About Feedback

 

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment, with greater connectivity across organisations.

 

Our products Bleepa® and CareLocker® work together to deliver unparalleled value to our customers. Bleepa® is our application layer and sits on top of CareLocker® as our data layer. Bleepa® is a clinician facing platform that displays clinical results from a patient's CareLocker® at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker® data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.

 

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRGZGMLNRKGDZM
Date   Source Headline
25th Feb 20114:04 pmRNSDirector/PDMR Shareholding
22nd Feb 20118:00 amRNSHalf Yearly Report
18th Feb 20114:16 pmRNSDirectorate Change
11th Feb 201111:58 amRNSDirectorate Change
29th Nov 201010:08 amRNSDirector/PDMR Shareholding
29th Oct 20107:00 amRNSFinal Results
29th Apr 20107:00 amRNSDirector/PDMR Shareholding
28th Apr 20107:00 amRNSDirector/PDMR Shareholding
24th Feb 20107:00 amRNSInterim Results
30th Oct 200911:30 amRNSFinal Results
12th Aug 20097:00 amRNSDirectorate Change
17th Feb 20097:00 amRNSHalf Yearly Report
8th Dec 20084:42 pmRNSDirectorate Change
19th Nov 20087:00 amRNSDirector/PDMR Shareholding
23rd Oct 20087:00 amRNSDirector/PDMR Shareholding
15th Oct 20084:59 pmRNSDirector/PDMR Shareholding
9th Oct 20087:00 amRNSFinal Results
2nd Jun 200812:37 pmRNSHolding(s) in Company
30th May 20085:38 pmRNSTotal Voting Rights
21st May 200811:45 amRNSResult of EGM
24th Apr 20087:55 amRNSProperty Purchase
4th Apr 20087:01 amRNSDirectorate Change
26th Mar 200810:06 amRNSDirectorate Change
28th Feb 20088:06 amRNSInterim Results
11th Feb 20089:21 amRNSUpdate on CVA
10th Jan 20087:00 amRNSDirectorate Change
10th Dec 20075:23 pmRNSCapital Reorganisation
10th Dec 20074:00 pmRNSCapital Reorganisation
13th Nov 20077:00 amRNSDirectorate Change
26th Oct 20073:45 pmRNSDirector/PDMR Shareholding
25th Oct 20071:13 pmRNSOffer Talks Terminated
17th Oct 20071:39 pmRNSStatement re Possible Offer
27th Sep 20077:01 amRNSFinal Results
16th Aug 20079:02 amRNSAIM Rule 26 Information
31st Jul 20073:45 pmRNSTotal Voting Rights
25th Jul 20078:26 amRNSDirectorate Change
20th Jul 20074:41 pmRNSDirector/PDMR Shareholding
18th Jul 20074:07 pmRNSHolding(s) in Company
17th Jul 20071:06 pmRNSHolding(s) in Company
9th Jul 20074:30 pmRNSHolding(s) in Company
5th Jul 200710:16 amRNSHolding(s) in Company
2nd Jul 20071:07 pmRNSResult of EGM
5th Jun 20077:02 amRNSIssue of Equity
2nd May 200711:03 amRNSHolding(s) in Company
30th Apr 200712:28 pmRNSTotal Voting Rights
30th Mar 200710:16 amRNSTotal Voting Rights
2nd Mar 20072:31 pmRNSIssue of Equity
7th Feb 20077:01 amRNSUpdate on Property Disposal
21st Dec 200611:29 amRNSTotal Voting Rights
19th Dec 20062:36 pmRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.